These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2726 related articles for article (PubMed ID: 28279251)

  • 21. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.
    Pandor A; Horner D; Davis S; Goodacre S; Stevens JW; Clowes M; Hunt BJ; Nokes T; Keenan J; de Wit K
    Health Technol Assess; 2019 Dec; 23(63):1-190. PubMed ID: 31851608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.
    Kongnakorn T; Lanitis T; Annemans L; Thijs V; Goethals M; Marbaix S; Wautrecht JC
    Clin Drug Investig; 2015 Feb; 35(2):109-19. PubMed ID: 25511639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.
    Dilokthornsakul P; Nathisuwan S; Krittayaphong R; Chutinet A; Permsuwan U
    Heart Lung Circ; 2020 Mar; 29(3):390-400. PubMed ID: 31000364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses.
    Wang X; Wang T; Chen X; Tian W; Ma D; Zhang J; Li Q; Chen Z; Ju J; Xu H; Chen K
    J Am Med Dir Assoc; 2023 Aug; 24(8):1233-1239.e26. PubMed ID: 37355246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.
    Bellinge JW; Paul JJ; Walsh LS; Garg L; Watts GF; Schultz C
    Med J Aust; 2018 Jan; 208(1):18-23. PubMed ID: 29320668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis.
    Wang Z; Xiang Q; Hu K; Zhang X; Xie Q; Liu Z; Cui Y
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):643-657. PubMed ID: 33817758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation.
    Sharma P; Scotland G; Cruickshank M; Tassie E; Fraser C; Burton C; Croal B; Ramsay CR; Brazzelli M
    Health Technol Assess; 2015 Jun; 19(48):1-172. PubMed ID: 26138549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation.
    Zhao YJ; Lin L; Zhou HJ; Tan KT; Chew AP; Foo CG; Oh CT; Lim BP; Lim WS
    Int J Cardiol; 2016 Oct; 220():794-801. PubMed ID: 27400183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonvitamin K antagonist oral anticoagulants in everyday practice: Stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
    Bentz BA
    J Am Assoc Nurse Pract; 2015 Dec; 27(12):721-31. PubMed ID: 26676209
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 137.